E 101

Drug Profile

E 101

Alternative Names: E-101; Zempia

Latest Information Update: 12 May 2015

Price : $50

At a glance

  • Originator Exoxemis
  • Class Antibacterials; Antifungals; Antivirals; Glucose oxidases; Peroxidases; Small molecules
  • Mechanism of Action Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative infections
  • Preclinical Bacterial infections; Mycoses; Viral infections

Most Recent Events

  • 12 May 2015 E 101 is still in phase III trials for Postoperative infections (Prevention) in the USA
  • 12 Sep 2012 Phase-III clinical trials in Postoperative infections (prevention) in USA (Topical, Liquid)
  • 02 Apr 2012 Preclinical trials in Mycoses in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top